We have built a strong network of partners with the best European academic research players, to transform their disruptive scientific discoveries into cutting-edge medicines or medical devices to diagnose and treat patients with severe diseases with high unmet medical need.
Our ambition is to work with leading European research centers to build the healthcare industry of tomorrow.
In that perspective, we have developed a unique approach. We work closely with the research teams early on to define a plan to validate their discoveries and bring together the best healthcare industry experts and later the most experienced entrepreneurs to create high-tech companies.
We provide capital/funding to the companies we have founded with our funds and invite other investors to join us. This new and distinctive approach makes us stand out from most players in the world of healthcare investment and has enabled us to build more than 10 companies over the past 10 years.
We are also involved in early stage companies that have already been created, but always by supporting their development by providing our expertise and network.
We have thus contributed to the financing of more than 40 companies, many of which have become recognized leaders in their respective sectors.
Because of our business, we are players in the world of healthcare and as such are committed to making our contribution to sustainable development. We adhere to the ESG practices we have established
| 2009 Co-creation of Kurma Partners by Thierry Laugel |
2009 Closing of Kurma Biofund I |
| 2010 Rémi Droller joins Kurma Partners |
2012 Sylvain Cascarino joins Kurma Partners |
| 2013 Closing of Kurma Biofund II |
2015 Closing of Kurma Diagnostics 1 |
| 2015 Alain Horvais and Philippe Peltier join Kurma Partners |
2016 Kurma Partners majority owned by its partners Partners acquired majority shareholding of the management company |
| 2017 Delegate management of Paris Saclay Seed Fund |
2018 First closing of Kurma Biofund III |
| 2019 Peter Neubeck joins Kurma Partners |
2019 Opening of the office in Germany |
| 2020 Final closing of Kurma Biofund III |
2020 First closing of Kurma Diagnostics II |
| 2020 Benjamin Belot joins Kurma Partners |
2021 Jean Francois Rivassou joins Kurma Partners |
| 2021 Final Closing of Kurma Diagnostics II |
2022 First Closing of Kurma Growth Opportunities |
| 2022 Daniel Parera joins Kurma Partners |
companies financed
since 2009
companies founded
since 2009
million €
under management
employees in
companies financed
